Alector Reports Q3 2025 Financial Results with Net Loss of $34.7 Million

Alector, Inc. reported its financial results for the third quarter of 2025, revealing a significant decline in collaboration revenue and a net loss of $34.7 million, compared to a net loss of $42.2 million in the same period last year. For the nine months ended September 30, 2025, the company recorded a net loss of $105.7 million, down from $117.0 million in the prior year. Collaboration revenue fell to $3.3 million for the quarter and $14.8 million for the nine months, a decrease of $12.1 million and $31.5 million, respectively, primarily due to the completion of performance obligations related to previous clinical trials.

Operating expenses also decreased, with total operating expenses for the third quarter at $40.9 million, down from $63.8 million in the same quarter of 2024. Research and development expenses were $29.4 million, a reduction of $18.6 million, attributed to decreased spending on the AL002 program and personnel costs following workforce reductions. General and administrative expenses also saw a decline, totaling $11.5 million compared to $15.8 million in the prior year. The company’s cash, cash equivalents, and marketable securities stood at $291.1 million as of September 30, 2025, providing a financial runway through 2027.

Strategically, Alector has faced challenges with its clinical programs, notably the discontinuation of the open-label extension of the INFRONT-3 Phase 3 trial for its candidate latozinemab, which did not meet its primary endpoint. The company has also made significant workforce reductions, cutting approximately 47% of its staff in October 2025 to align resources with its strategic priorities. This follows earlier reductions in 2023 and 2024, which were part of cost-cutting initiatives to focus on advancing its research pipeline.

Alector's operational metrics indicate a shift in focus towards its remaining product candidates, particularly nivisnebart, which is in Phase 2 clinical trials for Alzheimer’s disease. The company continues to rely on collaborations, particularly with GlaxoSmithKline (GSK), for the development and commercialization of its product candidates. However, the recent amendments to the GSK agreement, which require Alector to fund a portion of the development costs, may impact its financial flexibility.

Looking ahead, Alector anticipates continued net losses as it invests in research and development activities. The company is focused on advancing its product candidates through clinical trials while managing its operational costs. Alector's future performance will depend on the successful development and commercialization of its therapies, as well as its ability to secure additional funding to support its ongoing operations and strategic initiatives.